Literature DB >> 938165

Distressing side-effects of minocycline hydrochloride.

W L Fanning, D W Gump.   

Abstract

Minocycline hydrochloride is a tetracycline derivative that has been advocated as the drug of choice in the treatment of meningococcal carriers. Recently, we studied a group of 30 patients who experienced a large number of side-effects after receiving minocycline for treatment of meningococcal meningitis. Twenty-seven of 30 (90%) suffered from dizziness, vertigo, ataxia, weakness, nausea, and vomiting. These symptoms appeared within the first 72 hours of taking minocycline, and disappeared within 48 hours of stopping the medication.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 938165

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  6 in total

1.  The effect of minocycline on potassium leakage from red cells: a study of the genetics and relationship to vestibular adverse reactions.

Authors:  B G Lannigan; D A Evans
Journal:  J Med Genet       Date:  1982-10       Impact factor: 6.318

2.  Neurological and Psychiatric Adverse Effects of Antimicrobials.

Authors:  Madison K Bangert; Rodrigo Hasbun
Journal:  CNS Drugs       Date:  2019-08       Impact factor: 5.749

3.  Side effects of minocycline: a double-blind study.

Authors:  W L Fanning; D W Gump; R A Sofferman
Journal:  Antimicrob Agents Chemother       Date:  1977-04       Impact factor: 5.191

4.  Cetocycline, tetracycline analog: in vitro studies of antimicrobial activity, serum binding, lipid solubility, and uptake by bacteria.

Authors:  R Proctor; W Craig; C Kunin
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

Review 5.  Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis.

Authors:  Alejandro Díaz-Borjón
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 6.  Cell-based and pharmacological neurorestorative therapies for ischemic stroke.

Authors:  Poornima Venkat; Yi Shen; Michael Chopp; Jieli Chen
Journal:  Neuropharmacology       Date:  2017-09-01       Impact factor: 5.250

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.